Patients with bronchiectasis in China have a high disease burden and a low rate of use of evidence-based treatments.

The FDA has granted priority review to brensocatib to treat patients with non-cystic fibrosis bronchiectasis, according to a ...

The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for ...

Insmed Incorporated INSM announced that the FDA has accepted its new drug application (“NDA”) seeking approval of its ...

Millions are affected by lung conditions, often unaware of risks. Asthma + Lung UK's Andy Whittamore shares tips for ...

interstitial lung disease, bronchiectasis, benign and malignant neoplasms, and lung transplantation. The Lung Institute has developed a comprehensive program across specialties with one site for ...

The Lung Transplant Program at Baylor St. Luke’s Medical Center is a national leader in advanced lung disease and offers a variety of options for patients in need of a lung transplant. Our team is led ...

Though asthma-related ER visits have dropped, advocates still worry about industry's impact on health. Could new Allegheny County leadership spell change?

The Bridgewater, N.J., biopharmaceutical company said brensocatib has the potential to become the first and only approved treatment for non-cystic fibrosis bronchiectasis, which causes the lungs' ...

Insmed's promising drug pipeline includes Brensocatib and Arikayce. See why INSM stock is a strong pick with multi-billion ...